Cancer Biomarker Market Is Predicted To Grow Swiftly Due To Growing Prevalence Of Malignancies Till 2025: Grand View Research, Inc.

The global cancer biomarkers market is expected to reach a value of USD 33.7 billion by 2025, based on a new report by Grand View Research, Inc. Growing initiatives for development of drugs targeting novel cancer biomarkers coupled with the introduction of technologically advanced companion diagnostic kits is estimated to provide the market with high growth potential. Increasing awareness about personalized medicines amongst patients is further anticipated to boost adoption of cancer biomarkers.

In addition, presence of favorable government initiatives for the development of novel cancer diagnostic techniques is a key factor for market growth. For instance, the National Cancer Institute (NCI) provides funding to more than 8 research areas pertaining to cancer biomarker development. Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health are some of the organizations providing funding for biomarker research.

People with high alcohol consumption, tobacco usage, unhealthy food habits, and sedentary lifestyle are reported to be 80% more at risk of developing cancer as compared to other individuals. Infections such as Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been studied to be related in cancer development.

U.S. cancer biomarkers market, by application, 2014 - 2025 (USD Billion)




Browse full research report on Cancer Biomarker Market Analysis:

Further key findings from the report suggest:

  • Breast cancer was the largest segment by revenue share in 2016 owing to high prevalence of this type of cancer
  • Lung cancer is estimated to be the fastest-growing type due to increasing research activities toward development of novel lung cancer biomarkers
  • Genetic biomarkers, being the highest used and easily detectable held the majority share of cancer biomarker market by biomolecule in 2016
  • However, epigenetic biomarkers are anticipated to witness lucrative growth due to increasing focus on finding the role of epigenetic modifications in cancer development
  • Cancer biomarkers are majorly used for diagnostic purpose owing to their high specificity
  • The personalized medicine segment is estimated to witness fastest CAGR of 15.0% over the forecast period
  • North America dominated in terms of revenue share in 2016 due to established R&D infrastructure and high acceptance of biomarker-based cancer testing in this region
  • Asia Pacific is anticipated to grow at a substantial growth rate till 2025 with CAGR of over 16.7%
  • Some of the major companies in the cancer biomarkers market are Abbott Laboratories; F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; Affymetrix Inc.; Illumina, Inc.; Agilent Technologies; Merck & Co. Inc.; Hologic, Inc.; Sino Biological Inc.; and Becton, Dickinson and Company
 For more information: http://www.grandviewresearch.com



Comments

Post a Comment

Popular posts from this blog

Epigenetics Market to Observe Strong Development by 2022

The global  epigenetics market  is expected to reach USD 16.31 billion by 2022, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of cancer and other diseases with epigenetic modification base is expected to drive market growth during the forecast period.  Diagnostic companies are coming up with new products such as antibodies specific for the detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is expected to attract pharmaceutical companies to collaborate for the development of therapeutic drugs.  Presence of pipeline drugs and their expected commercialization is anticipated to boost penetration rates over the forecast period. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the FDA for use in combination with Folfiri for the treatment of patients with metastatic colorectal cancer.  Technology advancements in the field of epigenetics especially pertaining to t
Read more

Increasing Incidences Of M&A Of CDMO/CRO With Big Pharma Companies To Drive Life Sciences BPO Market Growth Till 2024: Grand View Research, Inc.

Image
The  life sciences BPO market  is expected to reach USD 420 billion by 2024, according to a new report by Grand View Research, Inc. The lucrative growth is attributed to the growing demand for contract manufacturing of raw materials, Finished Dosage Forms (FDFs), medical devices, drug discovery services, regulatory services, pre-clinical and clinical trial services, and pharmacovigilance services.  The pharmaceutical and biotech industry invests heavily in the R&D sector to continuously introduce new molecules, devices, and treatments. The different stages of the drug development such as drug discovery, pre-clinical studies, and clinical trials require huge financial, technological, and human resources.  North America life sciences BPO market, by services, 2013 - 2024 (USD Billion) In order to cater to the growing needs of the industry, the outsourcing vendors are expanding their product and service offerings and they are targeting niche areas for long-term growth
Read more

U.S. Telehealth Market Is To Be $2.83 Billion By 2022: Grand View Research, Inc.

Image
U.S. telehealth market  is expected to reach USD 2.8 billion by 2022, according to a new report by Grand View Research Inc. Increasing access to basic healthcare is the major aim of telehealth along with improved healthcare quality and patient safety by early detection and diagnosis. According to a report published by the Agency for Health Care Research and Quality (AHRQ), implementation of telehealth solution improves quality of care delivery to patients.  The rising demand for self care and independent living along with the concept of home care is highly appealing to the population. The Rhode Island Partnership for Home Care reported that in 2014, over 20,000 citizens demanded for home care that led to approximately 1,000,000 visits by healthcare providers. Advantages that drive the higher adoption for home care include better psychological impact on patients, provision of friendly environment, care provision as per patient needs, and cost-effectiveness.  U.S. telehealth
Read more